Alzheimer’s division

Quote








Lmaooo that’s a red flag to anyone applying. What’s the qualification? Just be curious lol
Do you not smell the desperation?

That division won’t even be around in 2 years.
Oh and you want to cover a huge ass territory for the same pay that you have? Then you go right ahead. Hopefully you aren’t laid off before the drug gets to market because none of those new drugs have a proven clinical affect.
 








Donanemab treatment only caused brain swelling in 27% of patients; brain swelling can cause irreversible damage, including death.

Any "drug" with that high percentage of a serious side effect won't stand a chance.
 




anonymous said:
Donanemab treatment only caused brain swelling in 27% of patients; brain swelling can cause irreversible damage, including death.

Any "drug" with that high percentage of a serious side effect won't stand a chance.
Click to expand...


Good Lord, read the data on these drugs. It’s very small swelling. There hasn’t been any irreversible damage or death in thousands of patients. So far one died while taking Aduhelm, but it doesn’t look like she should have been on it to begin with. Had swelling in head years before starting. Plus, the issue was that the radiologist missed moderate ARIA-E, despite the fact that she experienced it in the P3 studies (not sure if she was on drug given that placebo patients experience ARIA-E & H). She continued on drug for 2 more months. THEN when she had symptoms - and the rarer more significant ones, the husband waited 2 days to take her in (had confusion and difficulties talking). When you have literally no other options for treatment, you’re willing to take the risk.
 




anonymous said:
Good Lord, read the data on these drugs. It’s very small swelling. There hasn’t been any irreversible damage or death in thousands of patients. So far one died while taking Aduhelm, but it doesn’t look like she should have been on it to begin with. Had swelling in head years before starting. Plus, the issue was that the radiologist missed moderate ARIA-E, despite the fact that she experienced it in the P3 studies (not sure if she was on drug given that placebo patients experience ARIA-E & H). She continued on drug for 2 more months. THEN when she had symptoms - and the rarer more significant ones, the husband waited 2 days to take her in (had confusion and difficulties talking). When you have literally no other options for treatment, you’re willing to take the risk.
Click to expand...

So, it's the radiologist's fault ... no wait ... it's the husband's fault. And expecting nursing home staff to be diligent enough to recognize when there's a brain swelling problem, well, fat chance of that happening. So then it'll be the nursing home staff's fault? Please tell us the company isn't just banking on a patient population too "addled" to complain.

But for donanemab, like Aduhelm, in the absence of a clearly demonstrable cognitive/functional benefit, one can't show an acceptable benefit-to-risk ratio because all you got is risk. Management essentially acknowleges this with their projection of "... very marginal sales of donanemab after potential approval later in the year ..."
 




anonymous said:
So, it's the radiologist's fault ... no wait ... it's the husband's fault. And expecting nursing home staff to be diligent enough to recognize when there's a brain swelling problem, well, fat chance of that happening. So then it'll be the nursing home staff's fault? Please tell us the company isn't just banking on a patient population too "addled" to complain.

But for donanemab, like Aduhelm, in the absence of a clearly demonstrable cognitive/functional benefit, one can't show an acceptable benefit-to-risk ratio because all you got is risk. Management essentially acknowleges this with their projection of "... very marginal sales of donanemab after potential approval later in the year ..."
Click to expand...

LMAO! You demonstrate your ignorance by writing about nursing home patients. You get how oncology drug data works, right? plenty of accelerated approvals which have even less data. When you have no other option and there’s som pretty decent data on benefit (cognition/function/behavior in this case), then many choose the risk, especially one this minimal. You talk like the whole damn brain is swelling. ARIA is seen even in patients not on drug. Your body naturally clears amyloid beta. When you have an excess, it builds up. Your body is still trying to remove it. When you remove a plaque or part of one that’s attached to tissue, you will get some swelling. Drama queen.
 
















These drugs are being approved because the FDA thinks that hypothetically their MOA coukd be beneficial to AD patients. So far there is no proof that they have any real clinical benefit. That’s why Biogen is about to fail.
If we can’t show clinical benefit then ours will fail too. Hopefully our trials will show clinical benefit
 








Top Bottom
Back
Quote